[1] Emery RW,Emery AM,Raikar GV,et al. Anticoagulation for mechanical heart valves:a role for patient based therapy[J]. J Thromb Thrombolysis,2008,25(1):18-25.
[2] 马风香,武金花,陈培恒.心脏瓣膜置换术后抗凝治疗的健康教育[J].中国医药导报,2009,6(18):158.
[3] 王兆钺.抗凝治疗及出血危险的研究现状[J].血栓与止血学,2011,17(5):231-233.
[4] 张魁,董然.中国人群瓣膜置换术后华法林个体化治疗最新研究进展[J].心肺血管病杂志,2012,3(2):217-219.
[5] Klein TE,Altman RB,Eriksson N,et al. Estimation of the warfarin dose with clinical and pharmaeogenetic data[J].N Engl J Med,2009,360(8):753-764.
[6] 余靓平,宋洪涛,曾志勇,等.基于药物基因组学的华法林给药模型的验证[J].中华心血管病杂志,2012,40(7):614-619.
[7] 王红娟,刘瑜,杨洁,等.药物基因组学方程对中国患者低强度华法林抗凝治疗剂量的预测效果分析[J].中华老年多器官疾病杂志,2012,11(8):584-587.
[8] 郑红艳,宋杰.CYP2C9和VKORC1基因多态性对华法林剂量的影响[J].医学综述,2011,17(2):178-180.
[9] Yang L,Ge W,Yu F,et al. Impact of VKORC1 gene polymorphism on inter-individual and interethnic warfarin dosage requirement-a systematic review and meta analysis[J].Thromb Res,2010,125(4):e159-e166.
[10] 谭胜蓝,彭娟,周新民,等.验证并比较华法林稳定剂量预测模型对中国心脏瓣膜置换术后患者预测准确性[J].中国临床药理学与治疗学杂志,2012,17(9):1026-1033.
[11] 王红娟,刘瑜,杨洁,等.中国患者华法林抗凝治疗剂量的药物基因组学相关性及药物基因组学方程的比较分析[J]. 中华老年多器官疾病杂志,2012,11(7):522-526.
[12] Tang GM,Wu E,Lam YY,et al. Role of warfarin pharmacogenetic testing in clinical practice[J].Pharmacogenomics,2010,11(3):439-448.
[13] Cen HJ,Zeng WT,Leng XY,et al. CYP4F2 rs2108622:a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement[J].Br J Clin Pharmacol,2010,70(2):234-240.
[14] 祝锦,张微,张伟娟,等.中国汉族人群华法林药物基因组学剂量预测公式比较[J].中国药学杂志,2011,46(24):1929-1934.